Lonza secures deal with ALSA Ventures to support its portfolio of biotechs 12-May-2022 By Jane Byrne This week saw Swiss CDMO, Lonza, announce a framework collaboration agreement with ALSA Ventures, a London based European biotech investment firm.
Abzena secures $65m to expand production capacity, mammalian biologics site set to come online 31-Mar-2022 By Jane Byrne Abzena, a global CDMO specializing in the integrated development and manufacture of complex biologics and bioconjugates, has secured $65M in new funding.
